Nivolumab+Ipilimumab+RT in MSS mCRC
Nivolumab+Ipilimumab+RT in MSS mCRC
Active, not recruiting · NCT04575922 · Registry updated 2022-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab+Ipilimumab+RT in MSS mCRC | Metastatic Microsatellite Stable Colorectal Cancer | Active, not recruiting | Phase 2 | 2022-09-08 | NCT04575922 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Massachusetts General Hospital | 758 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |